Breaking Through Market Access Hurdles in Inpatient Drug Launches
Samatha, Editorial team, Pharma Focus Europe
Introduction of inpatient drugs in the current pharma climate is a formidable ordeal because market entry obstacles are complicated. These barriers are a result of reimbursement, formulary barriers, administrative blockades, and stakeholder inconsistency. This article reviews the assessment of strategic and operational barriers to inpatient drug launches and offers practical ways of overcoming barriers to access, such as engagement of stakeholders, demonstration of value, modeling of health economics, and implementation of early access initiatives.
The drugs used inpatient settings in a hospital or clinic are vital in the treatment of severe and life-threatening conditions. Nonetheless, access to the market of these therapies is littered with access barriers that threaten to constrain or slow the availability of such therapies to patients. Otherwise, unlike drugs that are outpatient, there are other pressures associated with inpatient products, which include the hospital reimbursement systems, the procurement procedures as well as the integration of the clinical pathways.
Payers and providers are facing pressure to rationalize every new therapy as drug prices keep going up. Such pressure is even more exacerbated in the inpatient environment in which expenditures may be bundled, frequently under a Diagnosis-Related Group (DRG) payment scheme, with little tolerance to highly expensive innovations unless they can show a tangible and visible benefit.
An effective market entry of an inpatient drug would therefore not only need regulatory green light but also a very complex plan of surmounting market access barriers.
1. Inpatient Drugs: What Are Inpatient Drugs?
The inpatient drugs are medicines taken in a hospital and are usually acute or complex cases resulting in infections, cancer, or failure of the organs or after operating. Examples are intravenous antibiotics, chemotherapy and monoclonal antibodies, and special biologics.
Such treatments tend to be very expensive, they must be done by professionals, and are placed in comprehensive treatment routines. They tend to be incorporated into the overall care cost of the hospital, therefore their reimbursement is more intricate in comparison to those in outpatient situations.
2. Key Stakeholders in Market Access
• The path to market access for inpatient drugs is full of many stakeholders:
• Public and Private insurers (payers)
• Hospital administrators
• Pharmacy and Therapeutic (P&T) committees
• Formulary decision-makers
• Physicians and clinical leadership
• Health Technology Assessment (HTA) agencies
The stakeholders are the most important people and they are brought in with varied expectations and models of decision-making. It is essential that interest alignment exists to access and uptake.
Major Market Access Hurdles
1. The Barriers to Formulary and P&T Committee
Formularies in hospitals are very strict and it may take long periods of the presentation of evidence and negotiation to make a new drug an inclusion. P&T committees require effective clinical and economic data in order to accept a new product, especially when it is an expensive one.
Non formulary drugs would experience restricted use because doctors could not prescribe them except by special means or a special exception process.
2. Reimbursement Challenges
Fixed payments are often made by many hospitals at the basis of DRGs which include all the costs of care and drugs. New drug which is considerably dearer than alternatives when they are not reimbursed separately may not be adopted by the hospitals since the financial outflow would be unacceptable.
The mitigation of this issue may be obtained through new technology add-on payments (NTAP) or pass-through status, where thorough planning and evidence provision is necessary.
3. Integration of Clinical Pathway
Clinical pathways are becoming more common in hospitals as standardized treatment programs. Unless a new drug is listed in these pathways, then they might not be prescribed no matter the usefulness of the new drug.
Requiring the drug to be included in such protocols involves educating a physician, providing evidence of its effectiveness, and being consistent with previously established targets of treatment.
4. Procurement and Budget Cycles
Hospital procurement processes are complex, often requiring months of lead time. Budget planning cycles can delay the inclusion of a drug even after it has received approval. This can significantly affect the time to peak sales.
Strategies to Break through Access Barriers
1. Start Market Access Planning Early
One of the most common pitfalls is delaying market access planning until after regulatory approval. Successful companies start planning 18–24 months before launch. This includes:
• Mapping stakeholders
Naming main people and institutions making decisions on obtaining healthcare. These are clinicians, payers, regulators, and patient advocacy groups.
• Formulary gatekeepers and budget holders discussions
Identify who dictate healthcare budgets and determine which products they would like to include in formularies, i.e., hospital pharmacists, payers, and procurement managers.
• Learning the system of DRG and reimbursement
Comparing Diagnosis-Related Group (DRG) systems and national reimbursement models so as to learn how treatments are financed and charged. This aids with the forecasting of revenue opportunities as well as coverage channels.
• Coming up with a custom geography-specific access strategy
Developing region-based market access strategies according to the healthcare policies and regulations and the specific requirements of the stakeholder to maximize product uptake in every region.
2. Build a Robust Value Proposition
An intriguing value addition does not only speak of clinical efficacy; it has to measure:
• Compared to current treatments cost-effectiveness
The assessment of effectiveness of the new treatment in terms of the provision of better or the same results at reduced or similar expense. Backed to value-based-claims to adoption and reimbursement.
• Impact on length of stay or re-readmission rates
Measure the influence of the intervention to the length of stay, or the risk of readmission. This proves to be efficient with possible cost savings to health care providers.
• Budget an impact for hospitals and payers
Analyzing the financial effect of adopting the treatment on healthcare budgets. Helps determine affordability and aligns with payer expectations for economic sustainability.
• Enhancement of the quality of life of patients
An evaluation of the treatment in terms of its effects on physical, emotional or social well-being. Good patient outcomes will be able to uphold positive access and reimbursement decisions.
Budget impact models (BIMs) and cost-effectiveness analyses (CEAs) are some tools needed to illustrate a value to the decision-makers.
3. Creating Real-world evidence (RWE)
Clinical trial findings are usually restricted to a local or real world setting and as such hospitals usually seek validations. Collaboration with hospitals to collect early RWE may:
• Strengthen the access case
The evidence should be strong in terms of clinically and economic value and merit of the treatment. This facilitates pricing, reimbursement and inclusion in a formulary.
• Accommodate the NTAP applications
Create evidence to support New Technology Add-on Payment (NTAP) applications demonstrating that the treatment is both new and expensive and beneficial to care. This assists in gaining short term extra reimbursement.
• Create clinicians as advocates
Involve and train the key physicians on the benefits of the treatment to promote it. Adoption and access is influenced by the clinician support in the hospitals and healthcare systems.
RWE may be derived in an RWE from post-marketing research, observational research, and retrospective studies.
4. Proactive Stakeholders Engagement
This consists in discussing and communicating with the stakeholders as early as possible and frequently. This includes:
Physicians: Develop advocates to be used at the P&T committee review
Hospital pharmacists: Educate in the use of handling, administration, and supply chain
Payers: Cooperate on the outcome-based contracts as required
Patients: Propose unmet requirements and promote access
Access planning can be advised with multi-stakeholders by setting up advisory boards or panels, and gathering invaluable input.
5. Pursue Temporary Access Mechanisms
In many markets, there are mechanisms for early access or reimbursement while full HTA or pricing decisions are pending. These include:
• Programs of compassionate use
Make potential treatments available early in order to give patients with severe illnesses and no options early access. Assists in the collection of real-world data and the development of clinical support prior to the product receiving approval.
• Managed entry contracts (MECs)
It should be possible to conditional market access depending on particular outcomes, limits on usage, or data collection. Allows, in part, to deal with contingency regarding efficacy or cost consequences.
• Risk-sharing agreements
Pay based on performance or performance of treatment, which distributes the financial risk between the manufacturers and payers. Promotes the uptake and safeguards payer budgets.
• Temporary repayment codes
Provide interim coding and payment processes to new treatments subject to permanent reimbursement decisions. Advises access and generation of information early.
These are programs to produce early sales, accumulate RWE, and build momentum to come to full reimbursement.
6. Health Economics and Outcomes Research (HEOR)
When investing in HEOR capabilities, you will be able to increase your team members' confidence to:
• Customize an economic model to every market.
Sensitize local clinical practices, prices, and health care structure into cost-effectiveness and budget impact models. Makes sure that it is relevant and credible to regional stakeholders.
• Answer HTA questions
Give definite and evidence-based responses to any questions raised by the Health Technology Assessment (HTA) bodies. The decision supports positive access and reimbursement.
• Partner with hospitals to carry out value-based care programs
Collaborate with providers to promote the congruence of using treatment to outcomes-oriented objectives. Proves willing to change to enhance quality at a reduced cost.
Conclusion
Inpatient drug Launch is a high stake activity. The obstacles are high-payment complexity, stakeholder’s misalignment, and long access timelines are threats to success. However, all these barriers can be conquered.
To some significant degree, the proactive, evidence-based, stakeholder-oriented approach to market access can lead to the significant improvement in the chances of making a successful launch. Advanced planning, production of real-life data, econometrics, and innovative pricing have become some of the irreplaceable items in the new inpatient launch playbook.
The pharmaceutical firms need to transform their perspectives on access as a post-launch action and consider it as the keystone of development and commercialization. In this way, they will be assured that innovative therapies are delivered to the right patients in the nearest time possible.
Author Bio
Samatha, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Sam contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
